sHB-EGF intensive therapy for diabetes

AAV vector delivery of HB-EGF ECD and HGF NK1 to the pancreas addresses the limitations of existing T1D treatments by enhancing glucose metabolism and β-cell protection, achieving sustained glucose control and insulin secretion in T1D.

JP7868817B2Active Publication Date: 2026-06-02KAGOSHIMA UNIV +1
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
KAGOSHIMA UNIV
Filing Date
2025-04-01
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Current treatments for type 1 diabetes (T1D) are inadequate in effectively suppressing blood glucose elevation and promoting insulin secretion, and existing gene therapies using full-length HB-EGF have limited efficacy and safety concerns.

Method used

Utilizing an adeno-associated virus (AAV) vector to deliver nucleic acids encoding the extracellular domain (ECD) of HB-EGF and the N-terminal domain and kringle 1 (NK1) of hepatocyte growth factor (HGF) directly to the pancreas, bypassing liver accumulation, to enhance glucose metabolism and β-cell protection and regeneration.

Benefits of technology

The AAV-mediated delivery of HB-EGF ECD and HGF NK1 significantly suppresses blood glucose elevation and promotes insulin secretion in a dose-dependent manner, achieving long-term glucose control without inducing hypoglycemia, thus providing a safe and effective treatment for T1D.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007868817000001
    Figure 0007868817000001
  • Figure 0007868817000002
    Figure 0007868817000002
  • Figure 0007868817000003
    Figure 0007868817000003
Patent Text Reader

Abstract

The present invention provides: a therapeutic agent for diabetes in mammals comprising a heparin-binding epidermal growth factor-like growth factor ectodomain (HB-EGF ECD) fragment or a nucleic acid encoding the same; the preparation combining hepatocyte growth factor (HGF) or a fragment thereof or a nucleic acid encoding the same; and a therapeutic agent for diabetes in mammals comprising a substance that potentiates signal transduction via the HB-EGF receptors.
Need to check novelty before this filing date? Find Prior Art